Literature DB >> 35082443

Discovery of novel septacidin congeners from a high yield heterologous expression strain Streptomyces albus 1597.

Meng Chen1,2, Zhenju Cao3, Wei Tang1,2, Min Wang1,2, Yihua Chen4,5, Zhengyan Guo6,7.   

Abstract

Septacidin is an adenine nucleoside antibiotic with antifungal and antitumor activities. During the efforts to construct a better septacidin producer, we obtained a high yield strain S. albus 1597 by putting the biosynthetic gene cluster (BGC) of septacidin under the control of the constitutive strong promoter ermE*. S. albus 1597 could produce new septacidin congeners SEP-538 and SEP-552 with shorter fatty acyl chains. Moreover, SEP-624 with an unprecedented hydroxylated fatty acyl chain was also isolated from this titre improved strain, enriching the diversity of septacidins. SEP-552 showed moderate inhibitory effects against Epidermophyton floccosum 57312 with MIC value 62.5 μM, while SEP-538 and SEP-624 only exhibited weak antifungal activities. The structure-activity relationship investigation revealed that the antifungal activity of septacidins is significantly influenced by the length of and the decoration on their fatty acyl chains.
© 2022. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35082443     DOI: 10.1038/s41429-022-00499-6

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  SEPTACIDIN, A NEW ANTITUMOR AND ANTIFUNGAL ANTIBIOTIC PRODUCED BY STREPTOMYCES FIBRIATUS.

Authors:  J D DUTCHER; M H VONSALTZA; F E PANSY
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1963

2.  Septacidin analogues.

Authors:  A Aszalos; P Lemanski; B Berk; J D Dutcher
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

3.  Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.

Authors:  M Kamishohara; H Kawai; T Sakai; T Isoe; K Hasegawa; J Mochizuki; T Uchida; S Kataoka; H Yamaki; T Tsuruo
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.